HRP20100086T1 - (2R,4aR,10bR)-6-(2,6-DIMETOKSIPIRIDIN-3-IL)-9-ETOKSI-8-METOKSI-1,2,3,4,4a,10b-HEKSAHIDROFENANTRIDIN-2-ol, HCI SOL - Google Patents

(2R,4aR,10bR)-6-(2,6-DIMETOKSIPIRIDIN-3-IL)-9-ETOKSI-8-METOKSI-1,2,3,4,4a,10b-HEKSAHIDROFENANTRIDIN-2-ol, HCI SOL Download PDF

Info

Publication number
HRP20100086T1
HRP20100086T1 HR20100086T HRP20100086T HRP20100086T1 HR P20100086 T1 HRP20100086 T1 HR P20100086T1 HR 20100086 T HR20100086 T HR 20100086T HR P20100086 T HRP20100086 T HR P20100086T HR P20100086 T1 HRP20100086 T1 HR P20100086T1
Authority
HR
Croatia
Prior art keywords
salt according
hexahydrophenanthridin
dimethoxypyridin
ethoxy
methoxy
Prior art date
Application number
HR20100086T
Other languages
English (en)
Inventor
Kautz Ulrich
Webel Matthias
Scheufler Christian
Hummel Rolf-Peter
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of HRP20100086T1 publication Critical patent/HRP20100086T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)

Abstract

Spoj, naznačen time, da je (2R,4aR,10bR)-6-(2,6-dimetoksipiridin-3-il)-9-etoksi-8-metoksi-1,2,3,4,4a,10b-heksahidrofenantridin-2-ol hidroklorid. Patent sadrži još 8 patentnih zahtjeva.

Claims (9)

1. Spoj, naznačen time, da je (2R,4aR,10bR)-6-(2,6-dimetoksipiridin-3-il)-9-etoksi-8-metoksi-1,2,3,4,4a,10b-heksahidrofenantridin-2-ol hidroklorid.
2. Spoj, naznačen time, da je solvatni oblik soli u skladu sa zahtjevom 1.
3. Spoj, naznačen time, da je hidratni oblik soli u skladu sa zahtjevom 1.
4. Sol u skladu s bilo kojim zahtjevom 1 do 3, naznačena time, da je u kristaliničnom obliku.
5. Sol u skladu s bilo kojim zahtjevom 1 do 4, naznačena time, da je u krutom dozirnom obliku.
6. Sol u skladu s bilo kojim zahtjevom 1 do 4, naznačena time, da je za uporabu u liječenju bolesti.
7. Farmaceutski pripravak, naznačen time, da sadrži sol u skladu s bilo kojim zahtjevom 1 do 4 zajedno s farmaceutskim pomoćnim tvarima i/ili punilima.
8. Uporaba soli u skladu s bilo kojim zahtjevom 1 do 4, naznačena time, da se koristi za pripremu farmaceutskih pripravaka za liječenje PDE4 posredovanih poremećaja.
9. Uporaba soli u skladu s bilo kojim zahtjevom 1 do 4, naznačena time, da se koristi za pripremu farmaceutskih pripravaka za liječenje diabetes mellitus-a.
HR20100086T 2005-03-02 2010-02-18 (2R,4aR,10bR)-6-(2,6-DIMETOKSIPIRIDIN-3-IL)-9-ETOKSI-8-METOKSI-1,2,3,4,4a,10b-HEKSAHIDROFENANTRIDIN-2-ol, HCI SOL HRP20100086T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05101619 2005-03-02
EP05108442 2005-09-14
PCT/EP2006/060377 WO2006092422A1 (en) 2005-03-02 2006-03-01 Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives

Publications (1)

Publication Number Publication Date
HRP20100086T1 true HRP20100086T1 (hr) 2010-04-30

Family

ID=36295528

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100086T HRP20100086T1 (hr) 2005-03-02 2010-02-18 (2R,4aR,10bR)-6-(2,6-DIMETOKSIPIRIDIN-3-IL)-9-ETOKSI-8-METOKSI-1,2,3,4,4a,10b-HEKSAHIDROFENANTRIDIN-2-ol, HCI SOL

Country Status (24)

Country Link
US (4) US7718668B2 (hr)
EP (3) EP1856093B1 (hr)
JP (2) JP5478828B2 (hr)
KR (2) KR101352687B1 (hr)
AT (1) ATE450524T1 (hr)
AU (1) AU2006219867B2 (hr)
BR (1) BRPI0607645A2 (hr)
CA (1) CA2598860C (hr)
CY (1) CY1109753T1 (hr)
DE (1) DE602006010824D1 (hr)
DK (1) DK1856093T3 (hr)
EA (1) EA015376B1 (hr)
ES (2) ES2337083T3 (hr)
HR (1) HRP20100086T1 (hr)
IL (2) IL185276A (hr)
ME (1) ME01172B (hr)
MX (1) MX2007010400A (hr)
NO (1) NO339416B1 (hr)
NZ (2) NZ589278A (hr)
PL (1) PL1856093T3 (hr)
PT (1) PT1856093E (hr)
RS (1) RS51345B (hr)
SI (1) SI1856093T1 (hr)
WO (1) WO2006092422A1 (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60311662T2 (de) 2002-08-29 2007-10-25 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
CA2556086C (en) 2004-02-18 2014-04-01 Altana Pharma Ag Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
CN104817534A (zh) 2004-03-03 2015-08-05 塔科达有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途
JP2007527901A (ja) * 2004-03-10 2007-10-04 アルタナ ファルマ アクチエンゲゼルシャフト アミド置換された新規のヒドロキシ−6−フェニルフェナントリジン及びpde4インヒビターとしてのそれらの使用
PL1856093T3 (pl) 2005-03-02 2010-05-31 Takeda Gmbh Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu
CN101511364B (zh) 2006-09-07 2012-08-15 奈科明有限责任公司 用于糖尿病的治疗组合
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
JP6038170B2 (ja) 2011-12-15 2016-12-07 アルカーメス ファーマ アイルランド リミテッド ブプレノルフィンおよびμ−オピオイド受容体アンタゴニストの組成物
CA2936332A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
JP7048863B2 (ja) 2016-08-26 2022-04-06 武田薬品工業株式会社 非アルコール性脂肪肝疾患の治療法
JP2020510071A (ja) 2017-03-16 2020-04-02 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 特発性肺線維症の治療

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027055D0 (en) 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
EE03523B1 (et) 1996-01-31 2001-10-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
ES2184077T3 (es) 1996-03-26 2003-04-01 Altana Pharma Ag Nuevas fenantridinas sustituidas en la posicion 6.
US6127378A (en) 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
TR199900856T2 (xx) * 1996-11-11 1999-07-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
WO1998040382A1 (en) 1997-03-07 1998-09-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel tetrazoles
PT988302E (pt) 1997-06-03 2003-07-31 Altana Pharma Ag Benzonaftiridinas
US6214839B1 (en) * 1997-07-25 2001-04-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted 6-alkylphenanthridines
DE69809754T2 (de) 1997-07-25 2003-09-18 Altana Pharma Ag Substituierte 6-phenylphenanthridine
CZ293725B6 (cs) 1997-07-25 2004-07-14 Altana Pharma Ag Tetrazolové deriváty
DK1075477T3 (da) * 1998-05-05 2003-06-30 Altana Pharma Ag Nye benzonaphthyridin-N-oxider
AU5970199A (en) 1998-08-31 2000-03-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity
CA2359404A1 (en) * 1999-01-15 2000-07-20 Beate Gutterer Phenanthridine-n-oxides with pde-iv inhibiting activity
ES2241571T3 (es) 1999-01-15 2005-11-01 Altana Pharma Ag N-oxidos de fenantrinida con actividad inhividora de pde-iv.
DE60033918D1 (de) 1999-01-15 2007-04-26 Altana Pharma Ag Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
PL205670B1 (pl) 1999-01-15 2010-05-31 Nycomed Gmbh Nowa 6-fenylofenantrydyna, jej zastosowanie oraz lek zawierający ten związek
DE60025327T2 (de) * 1999-01-15 2006-08-24 Altana Pharma Ag 6-arylphenanthridine mit pde-iv hemmender wirkung
CA2396026A1 (en) 2000-01-11 2001-07-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridine-n-oxides
ATE347557T1 (de) 2000-03-23 2006-12-15 Takeda Pharmaceutical Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
AU2001281965A1 (en) * 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Novel 6-phenylphenanthridines
AU2001283935B2 (en) 2000-07-14 2006-07-13 Altana Pharma Ag Novel 6-heteroarylphenanthridines
AU2001267589A1 (en) 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
DK1377574T3 (da) 2001-02-21 2005-04-25 Altana Pharma Ag 6-phenylbenzonaphtyridiner
WO2004018431A2 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
RS20050117A (en) 2002-08-17 2007-06-04 Altana Pharma Ag., Novel benzonaphthyridines
DE60310576T2 (de) * 2002-08-29 2007-10-31 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
DE60311662T2 (de) * 2002-08-29 2007-10-25 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
CA2556086C (en) * 2004-02-18 2014-04-01 Altana Pharma Ag Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
CN104817534A (zh) * 2004-03-03 2015-08-05 塔科达有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途
US20070191414A1 (en) * 2004-03-09 2007-08-16 Altana Pharma Ag Novel isoamido-substituted hydroxy-6-phenylphenanthridines
BRPI0508471A8 (pt) 2004-03-10 2019-01-15 Altana Pharma Ag compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos
JP2007527901A (ja) 2004-03-10 2007-10-04 アルタナ ファルマ アクチエンゲゼルシャフト アミド置換された新規のヒドロキシ−6−フェニルフェナントリジン及びpde4インヒビターとしてのそれらの使用
CA2558390A1 (en) 2004-03-10 2005-09-22 Altana Pharma Ag Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
PL1856093T3 (pl) 2005-03-02 2010-05-31 Takeda Gmbh Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu

Also Published As

Publication number Publication date
US20130096152A1 (en) 2013-04-18
ATE450524T1 (de) 2009-12-15
CY1109753T1 (el) 2014-09-10
US7718668B2 (en) 2010-05-18
EA015376B1 (ru) 2011-08-30
EA200701817A1 (ru) 2008-02-28
PT1856093E (pt) 2010-02-08
BRPI0607645A2 (pt) 2009-09-22
EP1856093A1 (en) 2007-11-21
US20080194587A1 (en) 2008-08-14
CA2598860C (en) 2017-01-17
EP2189454A1 (en) 2010-05-26
JP2014040482A (ja) 2014-03-06
EP1856093B1 (en) 2009-12-02
US8829189B2 (en) 2014-09-09
JP5478828B2 (ja) 2014-04-23
KR101352687B1 (ko) 2014-02-17
US8354535B2 (en) 2013-01-15
ES2440590T3 (es) 2014-01-29
KR101421914B1 (ko) 2014-07-22
IL185276A (en) 2013-10-31
US20140039001A1 (en) 2014-02-06
IL227565A (en) 2015-05-31
EP2295423A1 (en) 2011-03-16
JP2008531655A (ja) 2008-08-14
DE602006010824D1 (de) 2010-01-14
IL185276A0 (en) 2008-02-09
AU2006219867B2 (en) 2012-09-13
KR20070107157A (ko) 2007-11-06
NZ589278A (en) 2012-04-27
WO2006092422A1 (en) 2006-09-08
CA2598860A1 (en) 2006-09-08
US20100190818A1 (en) 2010-07-29
AU2006219867A1 (en) 2006-09-08
PL1856093T3 (pl) 2010-05-31
RS51345B (en) 2011-02-28
NO20074843L (no) 2007-09-24
NO339416B1 (no) 2016-12-12
ES2337083T3 (es) 2010-04-20
KR20130108475A (ko) 2013-10-02
US8754218B2 (en) 2014-06-17
SI1856093T1 (sl) 2010-03-31
DK1856093T3 (da) 2010-03-15
EP2189454B1 (en) 2013-09-25
EP2295423B1 (en) 2013-10-02
ME01172B (me) 2013-03-20
MX2007010400A (es) 2008-01-11
NZ560268A (en) 2010-12-24

Similar Documents

Publication Publication Date Title
HRP20100086T1 (hr) (2R,4aR,10bR)-6-(2,6-DIMETOKSIPIRIDIN-3-IL)-9-ETOKSI-8-METOKSI-1,2,3,4,4a,10b-HEKSAHIDROFENANTRIDIN-2-ol, HCI SOL
UA99136C2 (ru) Улучшенная фармацевтическая композиция, содержащая антагонист кальциевых каналов - лерканидипин, способ ее получения
IL259851A (en) Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders
ATE465719T1 (de) Oral zerfallende zusammensetzung von olanzapin oder donepezil
DK1487444T3 (da) Anvendelse af pyridylamider som angiogeneseinhibitorer
CL2007002705A1 (es) Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm.
MX2009003184A (es) Composiciones farmaceuticas que comprenden nilotinib o su sal.
JP2008513510A5 (hr)
GB0516168D0 (en) Pharmaceutical compounds
EA200702282A1 (ru) Комбинация феррохина и производного артемизинина для лечения малярии
CR20110209A (es) Composición farmacéutica sólida
BRPI0607214A2 (pt) derivados de 2-(4-cianofenilamino) pirimidina inibidores de hiv
DE602007013040D1 (de) 4-Ä(3-FLUORPHENOXY)PHENYLMETHYLÜPIPERIDINMETHANiSULFONAT: VERWENDUNGEN, SYNTHESEVERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
NO20074371L (no) Anthelmintiske imidazol-tiazolderivater
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
ATE489943T1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivate
CY1111067T1 (el) Χρηση της ν-(διβενζ (β,f) οξεπιν-10-υλμεθυλ) -ν-μεθυλ-ν-προπ-2-υνυλαμινης (omigapil) στην προληψη και/ή την θεραπεια της μυϊκης δυστροφiας
EA201001095A1 (ru) Соединение (r)-n*6*-этил-6,7-дигидро-5н-индено[5,6-d]тиазол-2,6-диамин и его применение в качестве антипсихотического средства
EA200970167A1 (ru) Фармацевтическая композиция, содержащая комбинацию саредутанта и селективного ингибитора обратного захвата серотонина или ингибитора обратного захвата серотонина/норэпинефрина
ATE415951T1 (de) Verbesserte pharmazeutische zusammensetzung mit einem ace-hemmer und herstellungsverfahren dafür
ITTO20050220A1 (it) Nuova utilizzazione terapeutica della molsidomina e dei suoi sali farmaceuticamente accettabili
WO2019190427A3 (en) The immediate release combination comprising raloxifene and at least one antipsychotic agent
MY150480A (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
ITCT20050012A1 (it) Preparato per uso orale, senza additivi, utilizzabile, nella profilassi di vitamina K microdosata, per la prevenzione dell'emorragia neonatale da deficit di ditamina K in forma tardiva.